FC
APGE

FORA Capital’s Apogee Therapeutics APGE Stock Holding History

FORA Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,099
Closed -$598K – 362
2026
Q1 		$598K Sell
7,099
-11,101
-61% -$806K 0.04% 289
2025
Q4 		$1.37M Buy
+18,200
New +$1.15M 0.17% 162
2024
Q4 		– Sell
-6,789
Closed -$399K – 386
2024
Q3 		$399K Buy
+6,789
New +$325K 0.05% 327

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

FORA Capital's APGE Position: Q2 2026 in Review

FORA Capital sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 7,099 shares — an estimated $598K sold.

FORA Capital first reported a position in APGE in Q3 2024 and held it in 3 quarters. The position peaked at $1.37M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • FORA Capital reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • FORA Capital sold 7,099 Apogee Therapeutics shares in Q2 2026, an estimated $598K.
  • FORA Capital first reported a position in Apogee Therapeutics in Q3 2024 and held it in 3 quarters.
  • FORA Capital's Apogee Therapeutics position peaked at $1.37M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.